Drug intelligence / Profile preview

StroMel

Development stage: Phase 2
Lead developer: Akan Biosciences
Modality: Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

StroMel is an investigational cell therapy composed of autologous mesenchymal stem cells (MSC) developed by Akan Biosciences. It is administered via intraarticular injection and is currently in Phase II clinical development for the treatment of knee, hip, and shoulder osteoarthritis, as well as wound healing and autism in children. The primary mechanism of action involves the paracrine signaling (secretion of extracellular vesicles/cytokines) that modulate immune responses, promote tissue repair, reduce inflammation, and support regeneration. Mesenchymal stem cells are also known to transfer mitochondria to nearby cells and may exert anti-fibrotic effects through immunomodulation[1][6][7][8].

Other names: stroMel

Beyond the preview

Go deeper on StroMel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StroMel.

Explore the full profile